Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal midazolam + ketamine dose comparison for sedation in non-cooperative pediatric dental patients
IRCT20090506001882N9Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of midazolam and ketamine in anxiety disorder (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Success of dental treatment according to Houpt Scale. Started Mar 2020; status: completed.
02
Drugs
midazolamketamine
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on IRCT20090506001882N9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090506001882N9.